checkAd

Caladrius Biosciences and Cend Therapeutics Announce Poster Presentation at the 2022 American Society of Clinical Oncology Annual Meeting

Poster Presentation to highlight ongoing clinical study of CEND-1 with FOLFIRINOX-based therapies in pancreatic, colorectal and appendiceal cancers

BASKING RIDGE, N.J. and SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, and Cend Therapeutics, Inc. (“Cend”), a privately-held, clinical-stage biopharmaceutical company focused on a novel approach to enable more effective treatments for solid tumor cancers, under their joint development agreement as part of their recently announced pending merger, today announced that data highlighting the ongoing clinical Phase 1b/2b study of CEND-1 in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colorectal, and appendiceal cancers will be presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting, being held from June 3–7, 2022 in Chicago, Illinois.

Details of the presentation are as follows:

  • Abstract Title: Phase Ib/IIa trial of CEND‐1 in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colorectal, and appendiceal cancers (CENDIFOX)
  • Abstract Number: 384156
  • Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
  • Session Type: Poster Session
  • Presenter: Anup Kumar Kasi, MD, MPH, University of Kansas Medical Center
  • Presentation Date & Time: Saturday, June 4th at 8:00am – 11:00am (CDT)

The full abstract will be released on May 26, 2022 at 5:00 PM (EDT). For more information about the 2022 ASCO Annual Meeting, please visit conferences.asco.org.

About CEND-1

CEND-1 is an investigational drug that modifies the tumor microenvironment. It is targeted to tumor vasculature by its affinity for alpha-v integrins that are selectively expressed in tumor, but not healthy tissue vasculature. CEND-1 is a cyclic peptide that, once bound to these integrins, is cleaved by proteases expressed in tumors to release a peptide fragment, called a CendR fragment, which binds to a second receptor, called neuropilin-1, to activate a novel uptake pathway that allows anticancer drugs to more selectively penetrate solid tumors. The ability of CEND-1 to modify the tumor microenvironment to enhance delivery and efficacy of co-administered drugs has been demonstrated in models of a range of solid tumors.

Seite 1 von 3



0 Kommentare
Nachrichtenquelle: globenewswire
 |  271   |   |   

Schreibe Deinen Kommentar

Disclaimer

Caladrius Biosciences and Cend Therapeutics Announce Poster Presentation at the 2022 American Society of Clinical Oncology Annual Meeting Poster Presentation to highlight ongoing clinical study of CEND-1 with FOLFIRINOX-based therapies in pancreatic, colorectal and appendiceal cancersBASKING RIDGE, N.J. and SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) - Caladrius Biosciences, Inc. …

Nachrichten des Autors

Titel
Titel
Titel
Titel